Results of a clinical trial to determine the efficacy and safety of adding rosuvastatin 10 mg to optimal therapy in patients with ischemic heart disease and systolic heart failure were presented as late-breaking research at the American Heart Association’s Scientific Sessions 2007.“Because patients with symptomatic heart failure were excluded from past placebo-controlled trials with statins, the benefits and risks of statins in the treatment of heart failure remain uncertain,” said Åke Hjalmarson, an investigator in the Sweden-based Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA). CORONA was designed to clarify the role of statin therapy in treating patients with systolic heart failure.
